For us, M&As are about calibrated aggression: Ramesh Swaminathan, CFO of Lupin

By Jasleen Kaur Batra

  • 23 Jun 2014

Mumbai-based Lupin Ltd is the second-largest pharma company in the country by market capitalisation behind Sun Pharma. It is dominant in the anti-TB and cephalosporin segment but is also a significant player in the cardiovascular, diabetology, asthma, paediatrics and anti-infective space. While the firm was active in pushing through an ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.